We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
1 own
3 watching
Current Price
$0
$-1.26
(-4.32%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
1,140.56M
52-Week High
45.989
52-Week Low
7.67
Average Volume
0.04M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,140.56M
52-Week High45.989
52-Week Low7.67
Average Volume0.04M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company s therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
20days ago
Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma PR...
Ticker Report
1month ago
Inhibrx, Inc. (NASDAQ:INBX Get Rating) CEO Mark Lappe sold 26,000 shares of the firms stock in a transaction that occurred on Monday, October 17th. The shares were sold at an average price of $29.59, for a total transaction of $769,340.00. Following the transaction, the chief ...
Ticker Report
2 months ago
Inhibrx (NASDAQ:INBX Get Rating) had its target price hoisted by equities research analysts at Evercore ISI from $54.00 to $60.00 in a note issued to investors on Wednesday, The Fly reports. The firm presently has an outperform rating on the stock. Evercore ISIs target ...
PR Newswire
2 months ago
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing PR Newswire PALM BEACH, Fl, Oct. 5, 2022 PALM BEACH, Fl, Oct. 5, 2022...
PR Newswire
2 months ago
Thinking about buying stock in Inhibrx, Playtika, Poshmark, Vir Biotechnology, or Ferroglobe? Thinking about buying stock in Inhibrx, Playtika, Poshmark, Vir Biotechnology, or Ferroglobe? PR Newswire NEW YORK, Oct. 4, 2022 NEW YORK, Oct. 4, 2022 /PRNewswire/ --InvestorsObserverissues critical...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-1.26
(-4.32%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00